C lassification of diseases has traditionally been shaped by expert consensus. As such, disease taxonomies are subject to the limits of existing knowledge and the biases of experts and may not reflect the underlying disease pathophysiology. In a landmark report Toward Precision Medicine, the Institute of Medicine called for improved approaches to developing disease taxonomies that classify complex diseases based on the molecular and clinical data of individual patients. 1 Here, we developed a comorbidity-driven taxonomy of pediatric pulmonary hypertension (PH) using data derived from administrative claims.
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It is well established that PH is a heterogeneous condition, often with a progressive and potentially fatal course. 2 centers, and half of those who had started receiving medication treatment for PAH were found to either have a different PH subtype or no PH at all. Indeed, misdiagnosis and misuse of therapies exposes patients to the potential side effects of therapies without the supposed benefits; for instance, therapies that are efficacious for PAH (eg, pulmonary vasodilator medications) may actually worsen pulmonary hemodynamics in PH associated with left heart disease, the most common cause of PH. 10, 11 The goal to optimize the treatment of PH based on its pathophysiology has led to the development of a formal taxonomy of PH by the World Health Organization (WHO). The taxonomy (WHO classification of PH) defines 5 distinct PH subtypes: PAH (group 1 PH), PH caused by left heart disease (group 2 PH), PH caused by chronic lung disease and hypoxia (group 3 PH), chronic thromboembolic PH (group 4 PH), and PH because of other multifactorial mechanisms (group 5 PH). 2 More recently, the realization that childhood-onset PH may have unique pathogeneses and association not often observed in adults further prompted the development of a new taxonomy for childhood-onset PH. [12] [13] [14] The taxonomy, known as the Panama classification (2011), highlighted a number of features more prominent in pediatric PH, including fetal and developmental origins of vascular disease. 13 Although these efforts provide a framework for the diagnosis and treatment of PH, gaps remain in our understanding of the disease, especially among children. Because of the rarity of PH in children, comprehensive analysis of its clinical manifestations is challenging. To date, published data on pediatric PH have been limited to several registry-based and small-cohort studies. 3, [15] [16] [17] [18] Although these studies have greatly advanced our understanding of the disease, they may be subject to referral bias and may not represent the full spectrum of pediatric PH cases. 19, 20 Furthermore, because knowledge generated from these studies formed the bedrock of the expert consensus classifications, current taxonomies may not capture the full spectrum of the diverse manifestations of PH.
We, therefore, seek to enrich and extend the current classifications of PH by applying network science methodologies to the largest data set of pediatric PH to date. Our goal is to facilitate improved recognition of clinically relevant patterns of disease manifestation, which can result in meaningful improvements in the timely and accurate diagnosis of PH.
The application of network science has transformed the study of biological systems. 21 Using network theory to model biological systems, nodes in the network represent biological entities (eg, gene, protein, and disease), and links between nodes represent the relationships between entities (eg, transcriptional regulation and correlation in gene expression levels). The emergent properties of a network can provide insights into biological processes that cannot be elucidated by studying individual entities in isolation. For example, gene coexpression network studies have revealed novel genes involved in the pathogenesis of various diseases, whereas protein interaction networks have led to the delineation of new disease pathways. In addition to genomic and proteomic studies, comorbidity networks modeling disease co-occurrence have been shown to capture phenotypic differences between patients with different demographic backgrounds, disease progression, and mortality. 22 Here, we apply for the first time a Bayesian network approach to characterize the comorbidity patterns in pediatric PH.
Methods
This is a retrospective cohort study of an insured population. As shown in Figure 1 , we (1) defined the comorbidity profiles of children What New Information Does This Article Contribute?
• Application of network science to model disease patterns captured in longitudinal data sets provides an unbiased approach to discovering disease subtypes.
• The approach identified rare and novel disease patterns in pediatric PH, providing impetus for deeper investigation that will enrich current disease classifications.
Classification of diseases has traditionally been shaped by expert consensus. As such, disease taxonomies are subject to the limits of existing knowledge and the biases of experts and may not reflect the underlying disease pathophysiology. Here, we establish for the first time the feasibility of applying network science to drive datadriven discovery of disease subtypes in pediatric PH. By modeling the complex interactions of disease symptoms recorded in longitudinal data sets, the approach automatically relearned PH subtypes with known pathological basis and further identified novel and rare disease patterns that are difficult to discern through clinical observations. Knowledge derived from the analysis will facilitate improved diagnosis of PH. Further advances linking disease subtypes to therapeutic response, disease outcomes, and the molecular profiles of individual subtypes will provide impetus for the development of more effective and targeted therapies. Although the current study focuses on pediatric PH, the proposed method has enormous potential for advancing our understanding of other complex diseases.
with PH; (2) constructed a Bayesian comorbidity network; and (3) applied network-clustering analysis to define disease subtypes.
Study Population and Data Extraction
To form our study cohort, we examined claims from Aetna, Inc, a major, nationwide employer-provided health insurance plan in the United States, between January 2010 and May 2013. Available information included dates of enrollment in the insurance program, outpatient visit claims, and inpatient visit claims. Demographic data included sex and age. All encounters were coded with International Classification of Diseases, Ninth Revision (ICD-9), codes. The Boston Children's Hospital Institutional Review Board approved the study and granted a waiver of consent. Subjects were drawn from 6 943 263 children (<18 years of age) enrolled in the insurer plan. A total of 1583 children met the criteria for PH, defined as having ≥2 healthcare visits associated We systematically identified all comorbidities significantly associated with PH, compared with the general population of children without PH. We defined the presence of a comorbidity as having ≥2 care encounters related to the condition, identified using ICD-9 codes. This approach has been previously validated for a wide range of diseases. [23] [24] [25] For example, Quan et al 24 showed that patients with hypertension can be reliably identified with high accuracy (specificity: 95% and sensitivity: 73%) when the diagnoses were defined as having ≥2 claims for hypertension within 3 years. We further conducted an additional sensitivity analysis, applying a more stringent algorithm that considered only diagnoses with ≥4 encounter visits. Using χ 2 statistic, we calculated the odds ratio with corresponding 95% confidence intervals and 2-tailed P values to measure the strength of the association between each comorbidity and PH. The α level of 0.05 was used to declare statistical significance. Bonferroni correction was applied to control for 767 comparisons with the adjusted α level being 0.000065.
Bayesian Comorbidity Network
We developed a Bayesian network to model the interdependencies of comorbidities in children with PH. We included in the model all comorbidities found to be significantly associated with PH compared with the general population of children without PH (Online Table  B1a ). We excluded comorbidities that occurred in fewer than 4 PH patients, because a small number of observations would not suffice to distinguish between true and spurious correlations. Schematically, the model is represented as a directed graph, with nodes representing comorbidities, and edges denoting statistically dependent relations among comorbidities. 26 An edge from node C i to C j can be interpreted as the presence of C i influences the occurrence of C j . The absence of a link between 2 nodes signifies conditional independence. Detailed description of the methods is provided in Section A1 in the Online Data Supplement.
Network-Clustering Analysis
To define PH subtypes, we partitioned the network into subgraphs comprising highly connected comorbidities using a strict partitioning rule whereby each comorbidity belongs to exactly one cluster. The graph partitioning process involves merging nodes agglomeratively, using a random walk clustering approach. 27 Detailed description of the methods is provided in Section A2 in the Online Data Supplement.
Evaluation
Review by experts evaluated our approach by checking for the identification of established PH subtypes. Accordingly, each comorbidity cluster was assigned a WHO and Panama classification subtype that best describes the cluster. For example, a comorbidity cluster comprising portal hypertension and the associated conditions would be classified as WHO group 1 (PAH associated with portal hypertension), and Panama group 10 (pediatric pulmonary vascular disease associated with other system disorders). Classification was first performed by 1 researcher (M.-S.O.) and then validated by 2 pediatric PH experts (M.H. and E.A.); inter-rater agreement was quantified using Cohen κ statistic, and discrepancies were resolved through consensus. The WHO and Panama classifications comprise 5 and 10 subtypes, respectively; the WHO classification further categorizes some of the 5 major subtypes into 26 minor subtypes ( Figure 1C ). To ascertain the sensitivity of our analysis, we measured the percentage of subtypes defined in WHO/Panama classifications that were captured by the network. We further conducted a literature review to evaluate network-derived clusters not described in either WHO or Panama classifications to assess whether published evidence supported the co-occurrence of PH with conditions captured by each cluster.
Secondary Analysis
To form the study cohort, we considered children who had ≥2 healthcare visits for PH. However, given that PH can often be miscoded 28 or misdiagnosed, 9,29 we may have inadvertently included patients who did not have PH. Definitive diagnosis of PH requires an elevated mean pulmonary arterial pressure of 25 mm Hg at rest measured by right heart catheterization (RHC). Hence, to address potential coding and diagnostic ambiguities, we performed a secondary analysis that considered only children who underwent RHC, in addition to having ≥2 healthcare visits for PH during the study period. A separate Bayesian comorbidity network was developed for this patient subgroup, and the differences in comorbidities and network-derived clusters were assessed.
Results
A total of 6 943 263 children were enrolled in the insurance plan and 1583 (0.02%) had ≥2 diagnosis codes for PH. The 6 940 062 children without any diagnosis codes for PH formed the control population for this study. A total of 186 comorbidities satisfied our study inclusion criteria (Online Table B1a ). When a more stringent algorithm for identifying diagnoses was applied, defined as having ≥4 healthcare visits during the study period, the association between PH and these comorbidities remained statistically significant, with the exception of pyogenic granuloma (Online Table B1b ).
The comorbidity burden of children with PH was substantial ( Figure 3 ). The mean and median number of comorbid conditions in individuals with PH were 7 and 8, respectively. Figure 4 depicts the Bayesian comorbidity network learned from the data set. The inferred network comprised 365 relations, described in further details in Online Table B2a . 
Network Analysis

Detection of Well-Established Subtypes
Cluster analysis of the comorbidity network identified all 5 major subtypes (sensitivity: 100%; κ score: 100%) and 19 of 26 minor subtypes (sensitivity: 73%; κ score: 96%) defined in the WHO classification (Table 1) , and 9 of 10 subtypes defined in the Panama classification (sensitivity: 90%; κ score: 90%; Table 2) , with a few anticipated exceptions. For example, in the absence of pedigree and genetic data, we were unable to discern the various forms of heritable PAH, with the exception of PH in association with hereditary hemorrhagic telangiectasia, a condition known to associate with PAH and linked to pathogenic variants in ALK1 and ENG genes. 30 The identification of pathogenic drugs and toxins associated with PAH is beyond the scope of this study. We were also unable to detect PH caused by chronic exposure to high altitude: the diagnostic code for the condition is nonspecific (ICD-9 993.2: other and unspecified effects of high altitude) and was not assigned to any of the patients in the study data set. The imprecision of ICD codes also precluded differentiation between left ventricular systolic and diastolic dysfunctions. Finally, we were unable to discern subtypes associated with HIV infection or schistosomiasis, because none of the PH patients in our US-based, privatelyinsured claims data set had billing codes for these conditions.
Detection of Rare Subtypes
Our analysis detected known rare associations with PH (Table 3 ). An example is the co-occurrence of PH with juvenile idiopathic arthritis and hemophagocytic syndrome. The clustering occurrence is not surprising given that PAH has been reported in several patients with systemic-onset juvenile idiopathic arthritis, particularly in association with macrophage activation syndrome. 31, 32 It has been hypothesized that PAH may be caused by exposures to interleukin-1 and interleukin-6 inhibitors used for treating systemic-onset juvenile idiopathic arthritis and macrophage activation syndrome 33 ; however, the underlying biology of this association remains unknown. In our data set, of 18 patients with both juvenile idiopathic arthritis and hemophagocytic syndrome, 4 patients developed PH, signifying the potential importance of this comorbidity pattern.
The cluster comprising glycogen storage disorder (GSD), hereditary muscular dystrophy, and cardiomyopathy typifies type 2 GSD. Although type 1 GSD has been linked to PH, the relationship between PH and type 2 GSD is less studied. A case report noted the development of PH resulting from respiratory muscular atrophy and alveolar hypoventilation caused by type 2 GSD. 34 Another report documented severe pulmonary veno-occlusive disease in a patient with type 2 GSD. 35 Another cluster captures the characteristic features of heterotaxy syndrome, including situs inversus, and congenital spleen anomaly. Of the 31 patients in our data set with these conditions, 4 developed PH. Several limited case reports documented the disease pattern in the setting of cardiac defects and pulmonary complications. 36, 37 We further identified several rare genetic disorders among the PH population, including Cri-du-chat, Turner, and PraderWilli syndromes. Case reports have documented the co-occurrence of PH in children with Cri-du-chat 38, 39 and Turner syndrome. 40, 41 PH in these patients may be caused by underlying congenital heart disease. In patients with Prader-Willi syndrome, obstructive sleep apnea and other obesity-related comorbidites may have contributed to the development of PH. In our data set, 6 (1.8%) of 329 patients with Prader-Willi syndrome developed PH. However, literature review yielded only 1 case report documenting a sudden death secondary to PH in a child with Prader-Willi syndrome, 42 indicating that the risk of PH in these patients may be under-recognized.
Although some clusters clearly describe syndromes with highly specific and rare comorbidities, other clusters contain unusual combinations of relatively more common conditions, which may represent unrecognized syndromes and generate new hypotheses. For example, the cluster comprising adrenogenital disorder, microcephaly, and adrenal hypofunction may represent Smith-Lemli-Opitz syndrome (SLOS), a rare condition caused by deficiency of 7-dehydrocholesterol reductase. Two potential pathogeneses would support the association between SLOS and PH. First, persistent pulmonary hypertension in newborn in SLOS has been documented in a patient with altered expression of caveolin-1 (CAV-1), 43 suggesting that caveolae-dependent signaling may be responsible for the pathogenesis of PH. This hypothesis was further strengthened in a recent study demonstrating an association between mutations in CAV-1 and PAH through whole-exome sequencing. 44 Second, cardiorespiratory problems can occur in individuals with SLOS, secondary to malformations of the heart or 
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We further identified a cluster containing comorbidities suggestive of Ehlers-Danlos syndrome (EDS), a group of genetically determined connective tissue disorders presenting with musculoskeletal dysfunction, encompassing a spectrum of symptoms such as hyperextensible skin, spontaneous ecchymoses, fragile vessels, and hypermobile joints with oftentimes secondary gait abnormalities. Spontaneous vascular or visceral rupture is a feature typifying vascular EDS, a rare subtype of EDS caused by mutations in the COL3A1 gene that result in increased fragility of connective tissue. In our study population, 2 of 11 children The association of PH with intestinal malabsorption and perinatal digestive system disorders may capture a rare treatable form of PH that is linked to chronic nutritional deficiencies. Severe vitamin deficiencies have been documented in patients with PH, whereby repletion of these vitamins led to the resolution of PH. A recent study showed a high prevalence of vitamin D deficiency in patients with PH and a significant inverse correlation between vitamin D serum levels and disease severity. 47 Furthermore, thiamine deficiency resulting in cardiovascular beriberi has also been reported as a rare reversible cause of PH. 48 PH associated with vitamin C deficiency in the setting of pulmonary complications has been documented in several patients. 49, 50 PH in these patients may be a result of reduced synthesis of NO, a potent mediator of vascular muscle relaxation. Vitamin C is also essential for the regulation of hypoxia-inducible family of transcription factors; deficiency in vitamin C can result in the inactivation of hypoxia-inducible factor activity, leading to deleterious pulmonary vasoconstriction and PH.
Discovery of Unknown Subtypes
Several network-derived comorbidity clusters do not fall into any of the categories in the WHO and Panama classifications. Of note, many of these clusters are linked to neurological defects not commonly thought to be associated with PH, including encephalocele, hydrocephalus, microcephaly, periventricular leukomalacia, and congenital brain reduction deformities (Table 4) . It is well established that children with severe neurological impairments are predisposed to respiratory problems that occur as a direct consequence of the underlying disability. For example, oropharyngeal motor problems associated with neurological dysfunctions can lead to recurrent aspiration and pneumonia. 51 Chiari malformation associated with hydrocephalus can cause both maldevelopment of the brain stem respiratory control centers and central sleep apnea. 52 Neurological impairments are also common among children requiring mechanical ventilation at the intensive care unit; PH in these patients may be secondary to mechanical ventilation management. Although we are unable to ascertain the causes of PH observed in our study cohort, our analysis suggests that the association of neurological defects with PH may be under-recognized and deserves further characterization.
Secondary Analysis: RHC Cohort
Of the 1583 patients included in the primary study cohort of children, 308 underwent RHC during the study period. Subject attrition was likely a result of the limited observation period captured in our data set, spanning a period of only 3 years; thus, patients who underwent RHC outside the study observation period would have been missed. Furthermore, published studies have consistently reported that many PH patients do not receive RHC as part of their diagnostic workup, despite being the diagnostic gold standard for PH. 9, 29, 53 Of the 186 comorbidities found to be significantly associated with PH in the primary study cohort, 168 were also significantly associated with PH in the RHC cohort, of which 119 were observed in ≥4 patients with PH (Online Table B1c ). A larger proportion of patients in the RHC cohort had congenital heart disease, compared with the primary cohort (86.0% [n=1361] versus 67.9% [n=209]; P<0.0001). This may reflect a higher utilization of RHC among PH patients treated by cardiologists. 29 There was also a substantial drop in the proportion of patients who had early-life respiratory conditions known to be associated with PH, including pulmonary hypertension in newborn (25 
P=0.0041).
A separate Bayesian comorbidity network was developed for the RHC cohort. The input of the network comprised 119 comorbidities that were significantly associated with PH and were observed in ≥4 patients in the RHC cohort. The inferred network contained 200 relations, described in further details in Online Table B2b .
Cluster analysis of the comorbidity network identified a subset of the subtypes derived from the primary study cohort. These included all the major subtypes (sensitivity: 100%; κ score: 100%) and 17 of 26 minor subtypes (sensitivity: 65%; κ score: 100%) defined in the WHO classification (Online Table B3a ), and 8 of 10 subtypes defined in the Panama classification (sensitivity: 80%; κ score: 100%; Online Table B3b ). Subtypes that were not captured included Situs inversus and congenital spleen anomaly This cluster captures the characteristic features of heterotaxy syndrome. PH associated with heterotaxy syndrome has been documented in several reports. 36, 37 Cri-du-chat syndrome, other chromosomal anomalies, other autosomal deletion syndromes, and rickets
Case reports have documented the co-occurrence of PH in children with Cri-du-chat, caused by underlying congenital heart disease. 38, 39 Turner syndrome (gonadal dysgenesis) and drug withdrawal syndrome Severe PH in the setting of cardiovascular abnormalities had been reported in children with Turner syndrome. 40, 41 Prader-Willi syndrome, abnormal weight gain, and aneurysm A case report documented a sudden death secondary to PH in a child with Prader-Willi syndrome. 42 Obstructive sleep apnea and other obesity-related comorbidities may have contributed to the development of PH.
Adrenogenital disorder, adrenal hypofunction, and microcephaly This cluster may represent SLOS. The co-occurrence of SLOS and PPHN or PAH has been documented in patients with altered expression of caveolin-1.
43,44
Disorder of muscle ligament and fascia, abnormality of gait, and spontaneous ecchymoses
This cluster contains symptoms suggestive of EDS. Spontaneous vascular or visceral rupture is a characteristic feature of vascular EDS, a subtype of EDS caused by mutations in the COL3A1 gene. The co-occurrence of EDS and mild PH has been documented in 2 patients. 46 Perinatal digestive system disorders and intestinal malabsorption Severe vitamin deficiencies in the setting of pulmonary complications have been documented in several patients with PH, whereby repletion of these vitamins led to the resolution of PH. [47] [48] [49] [50] EDS indicates Ehlers-Danlos syndrome; GSD, glycogen storage disorder; JIA Juvenile idiopathic arthritis; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; and SLOS, Smith-Lemli-Opitz syndrome.
PH associated with hereditary hemorrhagic telangiectasia, connective tissue disorders, systemic vasculitis, and GSDthese conditions were significantly associated with PH in the RHC cohort but were observed in fewer than 4 patients and were, therefore, excluded from the network analysis. Rare genetic disorders discerned in the primary analysis, such as Cri-du-chat and Prader-Willi syndromes, were also not captured in the network analysis because of the small number of patients with these conditions.
Discussion
We demonstrated that comorbidity patterns of patients with PH captured in a Bayesian network can be stratified into subtypes that are biologically and clinically informative. Our algorithmic methods automatically relearned most of the major PH subtypes with known pathological basis defined by the WHO classification. Although the similarity of the derived network structure to current taxonomy of PH provides face validity to the approach, it also offers some novel insights.
Specifically, the network approach enriches the current classification of PH. First, it captured several subtypes documented in only a few case studies for which evidence for systematic association remains lacking. This both validates the approach and provides impetus for deeper investigation of the disease subtypes. Clinicians should consider PH when dealing with patients with relevant conditions, whereas studies exploring the molecular and biological connections may reveal important insights. Our analysis also identified rare subtypes with findings consistent with several well-described genetic syndromes. Although we were unable to validate whether these patients indeed had the pathogenic mutations in the absence of genetic data, disease patterns identified through network analysis suggest future research in these areas may accelerate subtype discovery and relevance to PH more broadly. In the same way in which novel genetic associations in PH stimulate new avenues of research, so too may novel phenotypic associations prompt important discoveries related to disease susceptibility, and perhaps resiliency.
To construct the comorbidity network, we applied Bayesian model averaging technique to find a network model that best fits the underlying data. The approach is uniquely suited to accommodate the inherent uncertainties of biological processes and to minimize the effects of noise in the data. In maximizing specificity, however, other subtypes may have been missed. Furthermore, in defining comorbidity clusters, we have applied a strict partitioning rule, whereby each comorbidity belongs exactly to one cluster. Although this approach produces a model that is easier to interpret, the full expression of subtypes may not have been captured. As shown in Figure 4 , many comorbidities are linked to comorbidities belonging to another cluster. Of note, a majority of nodes are connected either directly or indirectly to congenital heart disease, the most common comorbidity in our study cohort. Shared features among multiple clusters may also reflect the overlapping phenotypes of PH, an increasingly recognized phenomenon.
14 Future research should explore methods that would facilitate the delineation of subtypes with overlapping manifestations and pathogeneses.
There are several limitations to our study. First, because our study relied on administrative claims, the diagnoses coded for billing purposes may not reflect actual comorbidities in the patients. To improve case identification specificity, we included only diagnoses with ≥2 encounter visits-an algorithm that has been validated in previous studies. [23] [24] [25] We further performed a sensitivity analysis with a more stringent case identification algorithm, considering diagnoses with ≥4 encounter visits during the study period; the association between PH and the identified comorbidities remained significant. Although it may not be possible to fully address diagnostic coding inaccuracies in administrative claims, we were able to discern comorbidity relations and derive subtypes that are biologically meaningful, thus lending support to the validity of the study approach. A further strategy we used to reduce uncertainties in our analysis is the exclusion of comorbidities that occurred in fewer than 4 patients and network relations with low probabilistic strengths (Methods A1 in the Online Data Supplement). In doing so, we may not have captured all the comorbidities and subtypes that were present in our study cohort.
A further limitation of our study lies in the difficulty in ascertaining the study cohort-in the absence of RHC results, we were unable to definitively confirm a diagnosis of PH. Nonetheless, the number of children with PH identified in the primary analysis was within the estimated population prevalence of PH. 17 We have also conducted a secondary analysis of children who underwent RHC and were diagnosed with PH. However, given the limited study period, and the persistent underuse of recommended diagnostic tests in contemporary clinical practice, 53, 54 restricting the study population results in the exclusion of several important subtypes. Nonetheless, the ability to reproduce similar subtypes based on the RHC cohort further validates the approach.
Claims data also have limited resolution, and because comorbidities associated with different PH subtypes can often coexist, we were unable to ascertain the PH subtypes of individual patients based on concomitant conditions alone. For example, patients with systemic sclerosis can have both PAH and pulmonary fibrosis; differentiating PAH from PH associated with pulmonary fibrosis can only be achieved through RHC. Finally, although our claims-based data set formed the largest data set on pediatric PH to date, we were unable to capture all PH subtypes seen globally, including those associated with HIV and schistosomiasis.
Although there are limitations to claims data, the availability of a large number of patients makes it possible to study the relationships between rare diseases, which may not have been observable in traditional studies involving chart reviews or surveys. Furthermore, claims data are systematically collected and provide longitudinal information that crosses facilities, geographical locations, and population demographics, thereby enhancing the generalizability of the research and limiting selection biases.
Conclusions
Data-driven discovery of disease phenotypes has enormous potential for advancing our understanding of complex diseases. By modeling the complex interactions of symptoms governing disease subtypes recorded in longitudinal data sets, rare subtypes that are difficult to discern through clinical observations can be identified. Further advances linking disease subtypes to therapeutic response, disease outcomes, and the molecular profiles of individual subtypes will provide impetus for the development of more effective and targeted therapies.
